Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 2/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.34 |
| ▸ | LOX | P28300 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29481424 | 0.91 | ROCK1 (0.47) | ROCK1PDPK1NR1H2GRM2LOXL2 | |
| SCHEMBL17221287 | 0.91 | ROCK1 (0.47) | ROCK1PDPK1NR1H2GRM2LOXL2 | |
| SCHEMBL29481438 | 0.91 | ROCK1 (0.47) | ROCK1PDPK1NR1H2GRM2LOXL2 | |
| SCHEMBL3738636 | 0.88 | SSTR4 (0.37) | PDPK1PLAUGRM2NR1H4HDAC3 | |
| SCHEMBL23012707 | 0.85 | ROCK1 (0.44) | ROCK1NR1H2GRM2NR1H4 | |
| SCHEMBL3743397 | 0.83 | PDPK1 (0.37) | PDPK1HDAC3HDAC1HDAC6SSTR4 | |
| SCHEMBL14416205 | 0.82 | HDAC8 (0.35) | PDPK1PLAUNR1H4HDAC3HDAC1 | |
| SCHEMBL7220504 | 0.81 | PLG (0.43) | PDPK1PLAUHDAC3HDAC1HDAC6 | |
| SCHEMBL22277233 | 0.81 | NR1H4 (0.40) | ROCK1PDPK1GRM2NR1H4 | |
| SCHEMBL18300147 | 0.81 | PDPK1 (0.35) | PDPK1NR1H4SSTR4SYKAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829584-B2 | Pyridines and pyridine N-oxides as modulators of thrombin | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-09 | — | — | US | disclosed |
| US-7829584-B2 | Pyridines and pyridine N-oxides as modulators of thrombin | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-09 | — | — | US | disclosed |
| US-20070225282-A1 | PYRIDINES AND PYRIDINE N-OXIDES AS MODULATORS OF THROMBIN | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-27 | — | — | US | disclosed |
| US-20070225282-A1 | PYRIDINES AND PYRIDINE N-OXIDES AS MODULATORS OF THROMBIN | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-27 | — | — | US | disclosed |
| WO-2007109459-A2 | PYRIDINES AND PYRIDINE N-OXIDES AS MODULATORS OF THROMBIN | JANSSEN PHARMACEUTICA, NV (BE) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109459-A2 | PYRIDINES AND PYRIDINE N-OXIDES AS MODULATORS OF THROMBIN | JANSSEN PHARMACEUTICA, NV (BE) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225282-A1 | PYRIDINES AND PYRIDINE N-OXIDES AS MODULATORS OF THROMBIN | F2, F11, TBXAS1 | ROCK1 475/4885PDPK1 2281/4885PLAU 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.